BCMLT
NAVB

Beacon Capital Management LLC (Tennessee)’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed -$1 – 1161
2023
Q4 		$1 Hold
10
– – ﹤0.01% 985
2023
Q3 		$1 Hold
10
– – ﹤0.01% 1025
2023
Q2 		$1 Hold
10
– – ﹤0.01% 1025
2023
Q1 		$3 Hold
10
– – ﹤0.01% 944
2022
Q4 		$2 Hold
10
– – ﹤0.01% 994
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1012
2022
Q2 		$0 Hold
10
– – ﹤0.01% 970
2022
Q1 		$0 Buy
+10
New +$9 ﹤0.01% 970

Other funds holding NAVB

PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s NAVB Position: Q1 2024 in Review

Beacon Capital Management LLC (Tennessee) sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2024, closing a stake of 10 shares — an estimated $1 sold.

Beacon Capital Management LLC (Tennessee) first reported a position in NAVB in Q1 2022 and held it in 8 quarters. The position peaked at $3 in Q1 2023. 2 funds tracked by Wall St. Rank hold NAVB as of Q1 2024.

  • Beacon Capital Management LLC (Tennessee) reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2024 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 10 Navidea Biopharmaceuticals Inc. shares in Q1 2024, an estimated $1.
  • Beacon Capital Management LLC (Tennessee) first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2022 and held it in 8 quarters.
  • Beacon Capital Management LLC (Tennessee)'s Navidea Biopharmaceuticals Inc. position peaked at $3 in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2024.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q1 2024, filed 16 May 2024.